SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy

Table 1 Demographic, clinical and therapeutic characteristics of the inflammatory bowel disease cohort

Therapy	Characteristics (n, %)	Disease		Total (n)
		CD (n)	UC (n)
Biologic treatment	Male (15, 41.6)	13	3	36
	Woman (20, 55.5)	15	5
	BMI > 30 (5, 13.8)	3	2
	BMI < 30 (31, 82.2)	25	6
	Comorbidities yes (14, 38.8)	11	3
	Comorbidities no (22, 61.2)	17	5
	Age > 65 (5, 13.8)	2	3
	Age < 65 (31, 86.2)	26	5
Azathioprine	Male (9, 64.2)	3	6	14
	Woman (5, 35.7)	2	3
	BMI > 30 (1, 7.1)	1	0
	BMI < 30 (13, 92.8)	4	9
	Comorbidities yes (6, 42.8)	2	4
	Comorbidities no (8, 57.1)	3	5
	Age > 65 (3, 21.4)	1	2
	Age < 65 (11, 78.6)	4	7
Mesalazine	Male (23, 43.4)	10	13	53
	Woman (30, 56.6)	11	19
	BMI > 30 (6, 11.3)	2	4
	BMI < 30 (47, 88.7)	19	28
	Comorbidities yes (30, 56.6)	10	20
	Comorbidities no (23, 43.3)	11	12
	Age > 65 (19, 35.8)	10	9
	Age < 65 (34, 64.2)	11	23
		54	49	103

BMI: Body mass index; CD: Crohn’s disease; UC: Ulcerative colitis.